Form 4: Xeris Biopharma Holdings Director Garheng Kong Acquires 50,000 Shares of Common Stock

Director Garheng Kong acquired 50,000 shares of Xeris Biopharma Holdings common stock through a restricted stock unit award.

Summary

• On June 5, 2024, Garheng Kong, a director of Xeris Biopharma Holdings, Inc., acquired 50,000 shares of common stock.
• The acquisition was made through a restricted stock unit (RSU) award under the company's 2018 Stock Option and Incentive Plan.
• Each RSU represents a contingent right to receive one share of Xeris Biopharma Holdings' common stock.
• The shares will vest in full on the earlier of June 5, 2025, or the date of the company's next annual meeting of stockholders.
• Following the transaction, Kong directly owns 164,144 shares of Xeris Biopharma Holdings common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports an insider transaction. It doesn't inherently indicate positive or negative prospects for the company.

Positives

• The acquisition of shares by a director may signal confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units is contingent upon the earlier of June 5, 2025, or the date of the company's next annual meeting of stockholders.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company directors.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.
• The acquisition of shares by a director may increase investor confidence.

Key Dates